Evaluation the role of the nephrology team in the specific vascular access outpatient clinic. What can we contribute new?

Background And Objectives: The key points of a monographic vascular access (VA) consultation are an adequate preoperative assessment, as well as a correct management and optimization of waiting lists. Our main objective of present study was to evaluate the degree of exploratory-dependent concordance in outpatient clinics regarding implanted VA, between nephrology and vascular surgery.

Materials And Methods: We analyzed VA created or surgically repaired between 2021 and 2022.

Identifying key genes in cancer networks using persistent homology.

Identifying driver genes is crucial for understanding oncogenesis and developing targeted cancer therapies. Driver discovery methods using protein or pathway networks rely on traditional network science measures, focusing on nodes, edges, or community metrics. These methods can overlook the high-dimensional interactions that cancer genes have within cancer networks.

Social representations of oncologic surgery for patients with cancer.

Objectives: to analyze the social representations of patients with cancer regarding oncologic surgery.

Methods: a qualitative study based on Social Representation Theory was conducted with 126 participants between October 2021 and May 2022 in a public hospital in Rio de Janeiro. A characterization questionnaire, free evocations of the inducing term "surgery", and semi-structured interviews with 60 participants were applied.

Active Learning Exercises in Synaptic Physiology and Connectivity for the Neuroscience Lecture Hall, Laboratory Course, or Outreach Setting.

It is well-understood that active learning approaches have positive learning outcomes and improve retention. Active learning strategies for the neuroscience laboratory setting have been extensively developed. Fewer active learning approaches are available for the traditional lecture-based setting.

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.

The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial comparing the immunogenicity and safety of the PHH-1V adjuvanted recombinant vaccine as a heterologous booster against homologous booster with BNT162b2. Interim results demonstrated strong humoral and cellular immune response against the SARS-CoV-2 Wuhan-Hu-1 strain and the Beta, Delta, and Omicron BA.1 variants up to day 98 post-dosing.